Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers-Reference-Cited by-同舟云学术

Generation of pralatrexate resistant T‐cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers

Published:2020-07-30 Issue:11 Volume:59 Page:639-651
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosomes Cancer

Author:

Scotto Luigi¹²^ORCID,Kinahan Cristina¹²,Casadei Beatrice¹²,Mangone Michael¹²,Douglass Eugene³,Murty Vundavalli V.⁴^ORCID,Marchi Enrica¹²,Ma Helen¹²,George Changchun¹²,Montanari Francesca¹²,Califano Andrea³,O'Connor Owen A.¹

Affiliation:

1. Center for Lymphoid Malignancies Columbia University Medical Center New York New York USA

2. Division of Experimental Therapeutics Columbia University Medical Center New York New York USA

3. Department of Systems Biology Columbia University Medical Center New York New York USA

4. Department of Pathology and Cell Biology Columbia University Medical Center New York New York USA

Publisher

Wiley

Subject

Cancer Research,Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/gcc.22884

Reference40 articles.

1. A historical‐perspective on key advances in the biochemistry and physiology of folates;Stokstad ELR;Abstr Pap Am Chem Soc,1988

2. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts

3. Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression

4. Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

5. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antifolate-based anticancer drugs;New Strategies Targeting Cancer Metabolism;2022

2. Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance;BMC Cancer;2021-07-31